OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS There were 26 patients with type 2 diabetes randomized to a 5-week double-blind, crossover study with a 6- to 8-week washout. Indirect calorimetry was used to measure 24-h energy metabolism and the respiratory exchange ratio (RER), both by whole-room calorimetry and by ventilated hood during a two-step euglycemic-hyperinsulinemic clamp. Results are prese...
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated i...
Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors (canagliflozin, dapagliflozin, empagliflozin...
Jean M Whaley,1 Mark Tirmenstein,2 Timothy P Reilly,2 Simon M Poucher,3 JoAnne Saye,4 Shamik Parikh,...
OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiov...
OBJECTIVE: SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment in type 2 diabetes mell...
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment in type 2 diabetes mell...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE Insulin resistance is associatedwithmitochondrial dysfunction and decreased ATP synthesis....
Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) modulate lipid metabolism and improve...
Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) modulate lipid metabolism and improve...
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated i...
Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors (canagliflozin, dapagliflozin, empagliflozin...
Jean M Whaley,1 Mark Tirmenstein,2 Timothy P Reilly,2 Simon M Poucher,3 JoAnne Saye,4 Shamik Parikh,...
OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiov...
OBJECTIVE: SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment in type 2 diabetes mell...
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment in type 2 diabetes mell...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardio...
OBJECTIVE Insulin resistance is associatedwithmitochondrial dysfunction and decreased ATP synthesis....
Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) modulate lipid metabolism and improve...
Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) modulate lipid metabolism and improve...
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated i...
Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors (canagliflozin, dapagliflozin, empagliflozin...
Jean M Whaley,1 Mark Tirmenstein,2 Timothy P Reilly,2 Simon M Poucher,3 JoAnne Saye,4 Shamik Parikh,...